Beckerle Mary C 4

What Happened

• Mary C. Beckerle, a director of Johnson & Johnson (JNJ), was granted 975 deferred share units (DSUs) on April 23, 2026. The filing lists the acquisition price as $0.00 (award/derivative); no immediate cash value was reported because DSUs are settled in cash later based on the fair market value of JNJ shares at settlement.

Key Details

• Transaction date: 2026-04-23 (Form 4 filed 2026-04-27).
• Grant: 975 DSUs; reported acquisition price $0.00 (code A — award/derivative).
• Shares/units owned after transaction: not disclosed in this Form 4.
• Footnotes: F1 — DSUs granted under the Amended and Restated Deferred Fee Plan for Directors are cash-settled upon termination, with each DSU equal to the fair market value of one share at settlement. F2 — DSUs include dividend equivalent rights that accrue with the issuer’s quarterly dividend.
• Timeliness: The Form 4 was filed four days after the transaction date, outside the typical two-business-day filing window for insider reports.

Context

• DSU grants are compensation and are cash-settled later, so they do not immediately change share count or signal a buy/sell decision. Dividend equivalents increase the eventual cash payout but do not represent current share ownership.